CIO 2021-10 Safety and Efficacy of Percutaneous Sotradecol (STS) Sclerotherapy for Treatment of Primary Aneurysmal Bone Cysts

Purpose: To evaluate the safety and efficacy of percutaneous Sotradecol (STS) sclerotherapy for treatment of primary aneurysmal bone cysts.

Material and Methods: We retrospectively reviewed 11 patients who underwent percutaneous 3% Sotradecol (STS) sclerotherapy between January 2015 and December 2020. Patients' ages ranged between 9 and 27 yrs. (median 14 yrs.). The patients underwent a total 24 percutaneous sclerotherapy (range 1-4, median 2). Clinical follow-up ranged 17 to 74 months (median 27 months). 9 patients were symptomatic, and 2 patients had incidentally discovered ABC’s. 7 out of the 11 patients underwent prior or simultaneous selective arterial embolization. 4 out of the 11 patients had recurrent ABC after surgery. The Society of Interventional Radiology adverse event classification system was used for evaluating complications.

Results: 8 out of the 9 (88.8%) symptomatic patients had complete clinical response.
1 patient had partial response after 1 sclerotherapy session and subsequently elected surgical treatment. Only SIR category 1 adverse events (mild AEs) were seen in 3 patients.

Conclusions: Our limited experience with percutaneous STS sclerotherapy for primary aneurysmal bone cysts suggests its safe and effective minimally invasive treatment for primary aneurysmal bone cysts.